NDC 0169-2911
Xultophy 100/3.6
(insulin Degludec And Liraglutide)
Xultophy 100/3.6 is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Insulin Degludec; Liraglutide.
| Product ID | 0169-2911_50d14aa3-54d6-4af2-9d25-99529af63053 |
| NDC | 0169-2911 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Xultophy 100/3.6 |
| Generic Name | (insulin Degludec And Liraglutide) |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2016-11-21 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208583 |
| Labeler Name | Novo Nordisk |
| Substance Name | INSULIN DEGLUDEC; LIRAGLUTIDE |
| Active Ingredient Strength | 100 [iU]/mL; mg/mL |
| Pharm Classes | Insulin [CS],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |